Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Target Price at $25.00

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has earned a consensus recommendation of "Buy" from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $23.80.

A number of research analysts have recently weighed in on KALV shares. Cantor Fitzgerald restated an "overweight" rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Bank of America initiated coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a "buy" rating and a $22.00 target price on the stock. JMP Securities began coverage on KalVista Pharmaceuticals in a research note on Friday. They set an "outperform" rating and a $19.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV traded up $0.54 during midday trading on Friday, hitting $9.76. 379,557 shares of the stock were exchanged, compared to its average volume of 291,849. The company has a market capitalization of $482.34 million, a PE ratio of -2.68 and a beta of 0.85. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $16.88. The business's fifty day simple moving average is $8.81 and its two-hundred day simple moving average is $10.81.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.01. As a group, equities analysts anticipate that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 7,627 shares of the firm's stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the completion of the transaction, the chief executive officer now directly owns 274,596 shares of the company's stock, valued at approximately $2,677,311. This trade represents a 2.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Venrock Healthcare Capital Par bought 43,707 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average cost of $8.76 per share, for a total transaction of $382,873.32. Following the purchase, the insider now owns 4,986,480 shares of the company's stock, valued at $43,681,564.80. This trade represents a 0.88 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders sold 32,291 shares of company stock valued at $304,086. 10.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. Suvretta Capital Management LLC raised its holdings in shares of KalVista Pharmaceuticals by 0.5% in the 3rd quarter. Suvretta Capital Management LLC now owns 4,212,005 shares of the specialty pharmaceutical company's stock worth $48,775,000 after buying an additional 20,000 shares in the last quarter. Vestal Point Capital LP increased its holdings in KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company's stock valued at $46,320,000 after purchasing an additional 1,700,000 shares in the last quarter. State Street Corp grew its stake in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company's stock valued at $14,725,000 after purchasing an additional 515,179 shares during the last quarter. Emerald Advisers LLC raised its position in shares of KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company's stock worth $9,681,000 after acquiring an additional 192,091 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of KalVista Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company's stock worth $9,624,000 after buying an additional 24,713 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).